Previous close | 862.00 |
Open | 866.00 |
Bid | 868.00 x N/A |
Ask | 870.00 x N/A |
Day's range | 863.00 - 879.00 |
52-week range | 612.00 - 895.00 |
Volume | |
Avg. volume | 2,883,900 |
Market cap | 87.384B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 33.68 |
EPS (TTM) | 25.77 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | 6.16 (0.71%) |
Ex-dividend date | 06 July 2023 |
1y target est | 909.00 |
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent’s Contract Development and Manufacturing Organization (CDMO), has clin
As of June 2024, Japan's stock markets have shown mixed signals, with the Nikkei 225 experiencing slight declines while the broader TOPIX Index has gained. This divergence reflects ongoing adjustments in monetary policy and external economic influences that could impact investor sentiment towards dividend stocks. In such a market environment, selecting dividend stocks requires a focus on companies with robust fundamentals and a history of stable dividend payouts, which can offer investors...